Physician profile
Bruce Spinowitz
NPI 1467475962
$465,246.24
in general payments reported to CMS, 2019-2025
24 companies · $123 in 2025
The $123 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $153K · 2020: $102K · 2021: $68K · 2022: $90K · 2023: $40K · 2024: $13K · 2025: $123.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $39K · Consulting Fee: $7,350 · Travel and Lodging: $4,181 · Food and Beverage: $1,631.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $39,325.00 |
| Consulting Fee | $7,350.00 |
| Travel and Lodging | $4,180.89 |
| Food and Beverage | $1,630.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $345,483.81 | 2019-2024 | Lokelma, Farxiga |
| Glaxosmithkline, LLC. | $45,480.37 | 2022-2024 | Jesduvroq, Benlysta |
| Bayer Healthcare Pharmaceuticals INC. | $17,614.28 | 2019-2023 | |
| Akebia Therapeutics INC | $16,457.04 | 2019-2025 | Auryxia, Vafseo |
| Fresenius USA Marketing, INC. | $12,557.63 | 2019-2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $11,045.95 | 2020-2021 | |
| Astrazeneca Uk Limited | $6,250.00 | 2020 | |
| Travere Therapeutics, INC. | $5,504.71 | 2022-2023 | |
| Otsuka America Pharmaceutical, INC. | $3,747.22 | 2019-2022 | |
| Vifor Pharma, INC. | $224.91 | 2019-2023 | Veltassa, Korsuva |
| Amgen INC. | $200.43 | 2019-2024 | Tavneos |
| Opko Pharmaceuticals, LLC | $140.34 | 2019-2022 | |
| Aurinia Pharma U.S., INC. | $101.64 | 2021-2023 | Lupkynis |
| Alexion Pharmaceuticals, INC. | $92.65 | 2019-2023 | Ultomiris |
| Daiichi Sankyo INC. | $76.71 | 2019-2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $66.57 | 2021-2023 | Krystexxa |
| Janssen Pharmaceuticals, INC | $50.84 | 2019-2020 | |
| Astrazeneca Ab | $50.34 | 2019 | |
| Alnylam Pharmaceuticals INC. | $28.84 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.84 | 2024 | Jardiance |
| Mallinckrodt Hospital Products INC. | $22.56 | 2022 | |
| Cumberland Pharmaceuticals, INC. | $22.56 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bruce Spinowitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.